BMO Capital Maintains Market Perform on Halozyme Therapeutics, Raises Price Target to $17

BMO Capital maintains Halozyme Therapeutics (NASDAQ:HALO) with a Market Perform and raises the price target from $16 to $17.

Benzinga · 11/13/2019 14:01

BMO Capital maintains Halozyme Therapeutics (NASDAQ:HALO) with a Market Perform and raises the price target from $16 to $17.